Habitual smoking causes an abnormality in platelet thromboxane A2 metabolism and results in an altered susceptibility to aspirin effects

被引:0
|
作者
Weber, AA
Liesener, S
Schanz, A
Hohlfeld, T
Schrör, K
机构
[1] Univ Dusseldorf, Inst Pharmakol, D-40225 Dusseldorf, Germany
[2] Univ Dusseldorf, Klin Pharmakol, D-40225 Dusseldorf, Germany
关键词
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The present study investigates the effects of aspirin (100 mg every second day for 14 days) on platelet function in nine healthy non-smokers and in nine healthy habitual smokers, There was a significantly (P<0.05) stronger inhibition of collagen (0.61 mu g/ml)- and ADP (2 mu M)-induced platelet aggregation by aspirin in smokers as compared to non-smokers. This difference occurred in the presence of an almost complete (>95%) inhibition of thromboxane A(2) (TXA(2)) synthesis in both groups, The platelet capacity to generate TXA(2) in vitro was significantly reduced in smokers, urinary excretion of TXA(2), however, was significantly increased. Thus, the better susceptibility of smokers to anti-aggregatory effects of aspirin is very likely to be related to a chronic smoking-induced alteration of platelet TXA(2) system. Cessation of smoking should, therefore, be encouraged.
引用
收藏
页码:177 / 182
页数:6
相关论文
共 48 条
  • [21] Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2
    Lucotti, Serena
    Cerutti, Camilla
    Soyer, Magali
    Gil-Bernabe, Ana M.
    Gomes, Ana L.
    Allen, Philip D.
    Smart, Sean
    Markelc, Bostjan
    Watson, Karla
    Armstrong, Paul C.
    Mitchell, Jane A.
    Warner, Timothy D.
    Ridley, Anne J.
    Muschel, Ruth J.
    JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (05): : 1845 - 1862
  • [22] Effects of platelet-activating factor and thromboxane A2 on isolated perfused guinea pig liver
    Ruan, ZH
    Shibamoto, T
    Shimo, T
    Koizumi, T
    Tsuchida, H
    Kurata, Y
    Ogura, T
    Kubo, K
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2004, 73 (1-2) : 73 - 85
  • [23] Inhibitory Effects of Resveratrol on Platelet Activation Induced by Thromboxane A2 Receptor Agonist in Human Platelets
    Yang, Yumin
    Wang, Xiaoling
    Zhang, Li
    An, Huiping
    Zao, Zhigao
    AMERICAN JOURNAL OF CHINESE MEDICINE, 2011, 39 (01): : 145 - 159
  • [24] Effects of the thromboxane A2 receptor antagonist on platelet deposition and intimal hyperplasia after balloon injury
    Yamagami, S
    Miyauchi, K
    Kimura, T
    Goh, Y
    Daida, H
    Yamaguchi, H
    JAPANESE HEART JOURNAL, 1999, 40 (06): : 791 - 802
  • [25] Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction
    Valles, Juana
    Santos, M. Teresa
    Fuset, M. Paz
    Moscardo, Antonio
    Ruano, Miguel
    Perez, Francisca
    Pinon, Marta
    Brena, Silvia
    Aznar, Justo
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (01): : 19 - 25
  • [26] Treatment of patients with vascular disease with low-dose aspirin.: Is blockade of platelet thromboxane A2 synthesis always achieved?
    Santos, M. T.
    Valles, J.
    Lago, A.
    Tembl, J.
    Cosin, J.
    Moscardo, A.
    Fuset, M. P.
    Breña, S.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 397 - 398
  • [27] EFFECTS OF LOW-TO-HIGH DOSES OF ASPIRIN ON PLATELET AGGREGABILITY AND METABOLITES OF THROMBOXANE-A2 AND PROSTACYCLIN
    TOHGI, H
    KONNO, S
    TAMURA, K
    KIMURA, B
    KAWANO, K
    STROKE, 1992, 23 (10) : 1400 - 1403
  • [28] EFFECTS OF THROMBOXANE A2 INHIBITION ON OSTEOGENIC-SARCOMA CELL-INDUCED PLATELET-AGGREGATION
    MEHTA, P
    LAWSON, D
    WARD, MB
    LEEAMBROSE, L
    KIMURA, A
    CANCER RESEARCH, 1986, 46 (10) : 5061 - 5063
  • [29] No correlation between thromboxane A2 synthesis and platelet activation in aspirin treated patients undergoing coronary artery bypass graft surgery.
    Favreau, Frederic
    Jayle, Christophe
    Bosc, Laure
    Christiaens, Luc
    Macchi, Laurent
    BLOOD, 2007, 110 (11) : 281A - 281A
  • [30] A novel thromboxane A2 receptor N42S variant results in reduced surface expression and platelet dysfunction
    Nisar, Shaista P.
    Lordkipanidze, Marie
    Jones, Matthew L.
    Dawood, Ban B.
    Murden, Sherina
    Cunningham, Margaret R.
    Mumford, Andrew D.
    Wilde, Jonathan T.
    Watson, Steve P.
    Mundell, Stuart J.
    Lowe, Gillian C.
    THROMBOSIS AND HAEMOSTASIS, 2014, 111 (05) : 923 - 932